Isolation of colistin-resistant Hafnia alvei

References

1. Bassetti M., Repetto E., Righi E., Boni S., Diverio M., Molinari M. P., Mussap M., Artioli S., Ansaldi F. other authors 2008; Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 61:417–420
   [Google Scholar]
2. Catchpole C. R., Andrews J. M., Brenwald N., Wise R. 1997; A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother 39:255–260 [CrossRef]
   [Google Scholar]
3. Gales A. C., Reis A. O., Jones R. N. 2001; Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 39:183–190 [CrossRef]
   [Google Scholar]
4. Girlich D., Naas T., Bellais S., Poirel L., Karim A., Nordmann P. 2000; Biochemical-genetic characterization and regulation of expression of an ACC-1-like chromosome-borne cephalosporinase from Hafnia alvei . Antimicrob Agents Chemother 44:1470–1478 [CrossRef]
   [Google Scholar]
5. Janda J. M., Abbott S. L. 2006; The genus Hafnia : from soup to nuts. Clin Microbiol Rev 19:12–18 [CrossRef]
   [Google Scholar]
6. Jones R. N., Anderegg T. R., Swenson J. M. the Quality Control Working Group 2005; Quality control guidelines for testing gram-negative control strains with polymyxin B and colistin (polymyxin E) by standardized methods. J Clin Microbiol 43:925–927 [CrossRef]
   [Google Scholar]
7. Kasiakou S. K., Michalopoulos A., Soteriades E. S., Samonis G., Sermaides G. J., Falagas M. E. 2005; Combination therapy with intravenous colistin for management of infections due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 49:3136–3146 [CrossRef]
   [Google Scholar]
8. Li J., Nation R. L., Milne R. W., Turnidge J. D., Coulthard K. 2005; Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 25:11–25 [CrossRef]
   [Google Scholar]
9. Markou N., Apostolakos H., Koumoudiou C., Athanasiou M., Koutsoukou A., Alamanos I., Gregorakos L. 2003; Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 7:R78–R83 [CrossRef]
   [Google Scholar]
10. Muyembe T., Vandepitte J., Desmyter J. 1973; Natural colistin resistance in Edwardsiella tarda . Antimicrob Agents Chemother 4:521–524 [CrossRef]
    [Google Scholar]
11. NCCLS 2003 Performance Standards for Antimicrobial Disk Susceptibility Tests . Approved Standard M2-A8 Wayne, PA: National Committee for Clinical Laboratory Standards;
    [Google Scholar]
12. Savini V., Catavitello C., Talia M., Di Berardino F., Manna A., Balbinot A., Febbo F., Carlino D., Fioritoni F. other authors 2008; Ulcer infection by ESBL-producing Proteus mirabilis : a case report. Int J Low Extrem Wounds 7:99–101 [CrossRef]
    [Google Scholar]
13. Shimizu S., Iyobe S., Mitsuhashi S. 1977; Inducible high resistance to colistin in Proteus strains. Antimicrob Agents Chemother 12:1–3 [CrossRef]
    [Google Scholar]
14. Tan T. Y., Ng S. Y. 2006; The in-vitro activity of colistin in gram-negative bacteria. Singapore Med J 47:621
    [Google Scholar]
15. Thomson K. S., Sanders C. C., Washington J. A. II 1993; Ceftazidime resistance in Hafnia alvei . Antimicrob Agents Chemother 37:1375–1376 [CrossRef]
    [Google Scholar]